Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial
Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · 399-407.e4
DOI: 10.1016/j.clml.2026.03.011 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Fjoralba Kristo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, MA, USA. Electronic address: Fjoralba.kristo@takeda.com. Hauptthemen laut MEDLINE: Hodgkin Disease, Peripheral Nervous System Diseases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Patient-reported outcome (PRO) data were analyzed to explore the experience of chemotherapy-induced peripheral neuropathy (CIPN) symptoms by patients with newly-diagnosed advanced-stage classic Hodgkin lymphoma (AS-cHL) treated with BrECADD versus eBEACOPP, and explore the association of CIPN symptoms with health-related quality of life (HRQoL). METHODS: Participants' experience was assessed during treatment and follow-up periods in a phase 3 trial of AS-cHL patients treated with BrECADD or eBEACOPP by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - core 30-item (QLQ-C30) questionnaire and the 20-item Chemotherapy-Induced Peripheral Neuropathy module (QLQ-CIPN20). Item responses were examined at each visit to describe the experience of CIPN symptoms per treatment arm. The association between patient-reported sensory symptoms and HRQoL was explored by describing PRO scores between participants with and without sensory symptoms. RESULTS: Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence followed a similar pattern over time across arms: they were reported during the treatment period, before gradually decreasing post-treatment. Motor symptoms were less reported than sensory symptoms. Participants with sensory symptoms showed poorer overall health and physical function, as well asmore fatigue than those without. DISCUSSION: These exploratory PRO analyses highlight the occurrence of CIPN-related sensory symptoms, and to a lesser extent, motor symptoms, of AS-cHL patients treated with multiagent regimens. Treatments such as BrECADD may be associated with fewer CIPN sensory symptoms, which could prevent detrimental effects on patients' HRQoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Takeda Development Center Americas, Inc., Cambridge, MA, USA. Electronic address: Fjoralba.kristo@takeda.com.
- Modus Outcomes, Lyon, France.
- Department I of Internal Medicine, German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, G…
- Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Zitieren
APA
Kristo, F., Mazerolle, F., Alin, T., Regnault, A., Ferdinandus, J., Behringer, K., Jablonski, J., Borchmann, P., & Ashaye, A. (2026). Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial. Clinical Lymphoma Myeloma and Leukemia, 26(6), 399-407.e4. https://doi.org/10.1016/j.clml.2026.03.011
Vancouver
Kristo F, Mazerolle F, Alin T, Regnault A, Ferdinandus J, Behringer K, et al. Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):399-407.e4. doi:10.1016/j.clml.2026.03.011
BibTeX
@article{Kristo2026,
author = {Kristo, Fjoralba and Mazerolle, Flora and Alin, Thibaud and Regnault, Antoine and Ferdinandus, Justin and Behringer, Karolin and Jablonski, Janina and Borchmann, Peter and Ashaye, Ajibade},
title = {Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {6},
pages = {399--407.e4},
doi = {10.1016/j.clml.2026.03.011}
}
EUVIMED